Brief: Lava Therapeutics Announces Initial Data From The Ongoing Phase 1/2A Clinical Trial Of Lava-1207 In Therapy Refractory Mcrpc At The 2023 Asco Gu Symposium

LAVA Therapeutics NV

16/02/2023 12:19

Feb 16 (Reuters) - LAVA Therapeutics NV  LVTX.O :
    * LAVA THERAPEUTICS ANNOUNCES INITIAL DATA FROM THE ONGOING
PHASE
1/2A CLINICAL TRIAL OF LAVA-1207 IN THERAPY REFRACTORY MCRPC AT
THE 2023 ASCO GU SYMPOSIUM
    * LAVA THERAPEUTICS NV - FAVORABLE SAFETY PROFILE TO DATE,
WITH NO
OCCURRENCE OF HIGH-GRADE (>2) CYTOKINE RELEASE SYNDROME OR
DOSE-LIMITING TOXICITIES
    * LAVA THERAPEUTICS NV - PRELIMINARY SIGNS OF ANTI-TUMOR
ACTIVITY
WERE OBSERVED, WITH IRECIST STABLE DISEASE (ISD) IN 8 OUT OF 14
EVALUABLE PATIENTS
    * LAVA THERAPEUTICS NV - DOSE ESCALATION IS ONGOING

Source text for Eikon:  ID:nGNXbxnr0k 
Further company coverage:  LVTX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))